As Amgen and AbbVie reveal first-quarter results, a clearer picture is beginning to emerge of the dynamics for biosimilar competition to Humira in the US. But Amgen is cautioning that Q2 sales of Amjevita may not match initial uptake in Q1.
Amgen has revealed the first sales information for its Amjevita (adalimumab-atto) biosimilar, following the firm’s launch of the first US rival to Humira earlier this year.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.
News of a fresh US investigation into the pharma sector has sparked renewed concerns over the impact that US trade tariffs would have on the generics and biosimilars industry. The AAM has responded with a warning over the potential effects on shortages and access, while Medicines for Europe has proposed five key action areas to bolster the sector in Europe.
Having failed in US patent litigation over Amgen’s Enbrel, Sandoz is taking an alternative approach in trying to get its Erelzi biosimilar to market in the US ahead of patent expiry in 2029: launching an antitrust attack against the originator for “unlawfully extending and entrenching its monopoly."
Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.
